Immune-Mediated Haemolytic Anaemia in Dogs

Immune-mediated haemolytic anaemia (IMHA) is a serious condition where a dog's immune system destroys its own red blood cells, requiring urgent veterinary intervention.

Key Facts

IMHA is one of the most common immune-mediated diseases in dogs
Cocker Spaniels, Miniature Schnauzers, and Poodles are at higher genetic risk
It can be primary (idiopathic) or secondary to infection, drugs, or cancer
Clinical signs include pale gums, rapid breathing, weakness, jaundice, and collapse
Packed cell volume (PCV) below 15% is life-threatening and may require transfusion
Treatment involves immunosuppressive doses of prednisolone plus additional agents like azathioprine
Mortality rates range from 30-50% even with intensive treatment

Welfare Considerations

IMHA causes profound suffering through severe anaemia, fatigue, and the physical effects of the immune response itself. Dogs with acute IMHA may collapse without warning, and the condition progresses rapidly. The treatment phase also involves welfare trade-offs: high-dose immunosuppression causes polyuria, polydipsia, increased appetite, behavioural changes, and infection susceptibility. Blood transfusions are stressful events requiring catheterisation, sedation, and prolonged hospital stays. Long-term management requires careful tapering of immunosuppressants over 3-6 months, with repeated blood tests monitoring PCV and reticulocyte counts. Owners need honest guidance about prognosis and quality-of-life assessment — some dogs relapse multiple times, and each relapse carries similar mortality risk. Good welfare monitoring includes appetite, energy, and demeanour alongside haematological parameters.

What You Can Do

Know the warning signs: pale gums, rapid breathing, and sudden weakness need emergency care
Ensure your dog is up to date with health checks to detect underlying triggers early
Ask your vet about prognosis and quality-of-life assessment at each stage
Consider pet insurance to cover the high cost of IMHA treatment and hospitalisation
Support veterinary research into better IMHA therapies with fewer side effects
Use clinical outcome questionnaires to track wellbeing during the long treatment phase